$EW

BOBO DONALD E JR sold $2.0M of EW (indirect holdings)

BOBO DONALD E JR (CVP,Strategy/Corp Development) sold 23,145 indirectly-held shares of Edwards Lifesciences Corp (EW) at $86.42 ($2.00M total) on 2026-05-27.

Original reporting
SEC EDGAR · BOBO DONALD E JR
Published May 27, 2026, 11:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 11:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EW
Neutral
medium confidence
Mentioned
$EW
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EWNeutralLow
01

Why it matters

Near-term trading impact is likely limited to sentiment/positioning rather than fundamentals, given no accompanying earnings, guidance, trial, or deal information.

02

Market read

A disclosed insider sale can cause brief negative read-through, but without fundamental catalysts it is unlikely to drive a durable repricing.

03

What to watch

The filing notes indirect ownership and does not confirm whether the sale was part of broader planned selling beyond the stated lack of a pre-arranged 10b5-1 plan; also, one Form 4 does not establish a trend.

Relevance 6/10Timing: Same-day/next-session sentiment check; likely limited follow-through.

Background

The article is an SEC Form 4 insider transaction disclosure for Edwards Lifesciences, filed the same day as the sale.

Company-level read

Ticker impact

$EWNeutralMedium confidence
Context

Edwards Lifesciences officer BOBO DONALD E JR sold 23,145 shares in an open-market transaction worth about $2.0M, disclosed via SEC Form 4.

Expected impact

Low probability of sustained price impact; any reaction is likely short-lived and sentiment-driven.

Evidence & confidence

Form 4 insider sales are common and often non-informational; absence of a stated 10b5-1 plan can increase interpretation risk, but the filing provides no new company-specific operational or financial information.

Market effects

Minimal; one-off insider sale in a medical device/healthcare name typically does not reset sector expectations.

None indicated; transaction is company-specific and US-listed.

None indicated; no international deal/regulatory/drug-trial content.

Counterpoint

Insider sales frequently reflect diversification, taxes, or routine liquidity needs and may not signal negative fundamentals—especially with a single transaction size.

Key entities

  • Edwards Lifesciences Corp

    Subject of the SEC Form 4 insider sale by an officer (CVP, Strategy/Corp Development).

  • BOBO DONALD E JR

    Officer who executed an open-market sale of 23,145 shares on 2026-05-27.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EWMedAI 8/10

CMS Expands Medicare Coverage for Edwards TAVR

CMS expanded Medicare coverage for Edwards Lifesciences' TAVR procedure to asymptomatic severe aortic stenosis patients. The company reiterated its 10-11% sales growth guidance. Shares (EW) fell 2.7% to $84.37. Analysts see upside, with Jefferies raising its price target to $105.

$EWMedAI 8/10

BD Taps Edwards Lifesciences Veteran Gary Sorsher to Lead Global Quality

BD appointed Gary Sorsher, former Chief Quality Officer at Edwards Lifesciences, as its new Executive Vice President and Chief Quality Officer. Sorsher brings over 30 years of experience in quality roles. The move follows Jeffrey Silvestri's planned retirement. BD's CEO highlighted Sorsher's global experience and focus on continuous improvement. Edwards Lifesciences received FDA clearance for its Ecliptis left atrial appendage exclusion system, entering the surgical stroke-prevention market. BD

$EWMed

Edwards Lifesciences, Medtronic score CMS win over TAVR

Edwards Lifesciences (EW) and Medtronic (MDT) welcomed CMS's decision to expand Medicare coverage for TAVR to asymptomatic severe aortic stenosis patients, citing improved access and streamlined care. EW shares fell 2% to $84.31, MDT dropped 1% to $90.70. CMS's decision was based on EW's Early TAVR trial data, showing lower adverse outcomes for prompt TAVR. Analysts view the decision as positive for TAVR growth.

$EWHigh

CMS TAVR changes, a boon for Edwards

The CMS has expanded Medicare coverage for TAVR procedures to include asymptomatic severe aortic stenosis patients. Edwards Lifesciences Corp. has advocated for this change, which may benefit the company.

$EWHighAI 8/10

Edwards Lifesciences stock price target maintained at $85 by Canaccord

Canaccord maintained a Hold rating and $85 price target for Edwards Lifesciences (EW) after a Medicare coverage decision on TAVR procedures. The stock trades at $86.77, above the target but below consensus. CMS finalized changes Edwards requested, expanding coverage for asymptomatic severe aortic stenosis. Edwards confirmed its 2026 financial guidance, expecting long-term benefits. Analysts have mixed price targets, ranging from $84 to $110. The company reported strong Q2 results, with sales of

$EWHighAI 8/10

Stifel sees CMS TAVR coverage update as positive for Edwards

CMS finalized TAVR coverage, benefiting Edwards Lifesciences due to its market leadership. Stifel analysts view the update positively, supporting Edwards' revenue growth outlook. TAVR represents 75% of Edwards' revenues and 5.5% of Medtronic's. CMS also initiated coverage analysis for devices treating aortic regurgitation, including Edwards' J-Valve.